Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

著者: Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, Helmut Albrecht, Paul E. Sax, Franco Maggiolo, Catherine Creticos, Claudia Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin - The Lancet 2019 被引用: 143